A Phase 1b Multicenter, Open-label Study To Evaluate The Safety And Tolerability And Determine The Maximum Tolerated Dose Of Pf-05230907 In Subjects With Intracerebral Hemorrhage (Ich)

Trial Profile

A Phase 1b Multicenter, Open-label Study To Evaluate The Safety And Tolerability And Determine The Maximum Tolerated Dose Of Pf-05230907 In Subjects With Intracerebral Hemorrhage (Ich)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs PF 5230907 (Primary)
  • Indications Cerebral haemorrhage
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 30 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 07 Sep 2016 Planned initiation date changed from 1 Oct 2016 to 1 Nov 2016.
    • 16 Aug 2016 Planned End Date changed from 1 Oct 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top